Business Wire

Citi Global Wealth Investments Issues Mid-Year Outlook 2021: Traveling to the post-COVID world - New portfolios for a new economy

Share

Citi Global Wealth Investments today released its Mid-Year Outlook 2021 report, Traveling to the post-COVID world: New portfolios for a new economy. Released twice yearly, Citi’s outlook explains why this recovery will be strong due to swift and deep government stimulus and vaccine effectiveness. This sets the stage for several new near-term and long-term opportunities for investors.

Citi Global Wealth Investments expects that digitization, climate change, increased US-Chinese competition and government spending policies will reshape industries. The pandemic focused attention on these issues and their economic impact will provide many companies with new growth potential. This allow portfolios to move beyond our previous approach of “exploiting mean reversion” that focused on investing in areas hardest hit by the recession and riding the recovery. Additionally, our eyes are also on the many governments that intend to make greater investment in infrastructure reshaping their own economies.

“Long before the arrival of effective vaccines, we made the case for a full recovery in the global economy. We advised clients to remain invested and to add to their equity allocations early on,” said David Bailin, Chief Investment Officer and Global Head of Investments for Citi Global Wealth. “Now, we look to exploit the trends that will reshape the world after COVID. We caution, however, that many of the best near- term investments aren’t necessarily those we envisage leading markets higher longer-term. We want client portfolios to evolve and reflect the transformational opportunities to come.”

Unprecedented monetary and fiscal easing measures, effective vaccines and tech-powered productivity improvements have helped lower the chances of another economic contraction any time soon. Therefore, Citi continues to recommend allocations toward regions and industries where valuations do not reflect a full recovery. We have recently moderated our peak equity allocation for the first time since early 2020. We’ve pivoted from some “early cycle outperformers” to global health care and dividend growth shares to try to identify more enduring returns.

As the economic recovery continues to play out, long-term bond yields are likely to trend higher. That is why we still have a large underweight in bonds. Citi has added floating bank rate loans to portfolios that can do better in such an environment.

“While much of what we highlight in Mid-Year Outlook 2021 are portfolio approaches that will benefit from a steadily improving economic recovery, we also note areas of caution,” said David Bailin. “These challenges could include COVID mutations and cybersecurity concerns. That is why we seek to preserve and grow wealth by way of a globally diversified asset allocation rather than taking highly concentrated risks.”

What has gained momentum is Citi Global Wealth Investment’s focus on “Unstoppable Trends”. The pandemic promoted digitization - how businesses and consumer alike embraced new technology to live and work; greening the world – the collapse of fossil fuel demand and energy prices during the first lockdown and what that means for the rollout of clean energy; and the rise of Asia – how strategic engagement between China and the U.S. will look in the future.

The full report, a summary version, short videos, and other materials can be accessed here.

Citi Global Wealth was formed in January 2021 to deliver Citi’s wealth solutions, products and services globally to help enable clients achieve their financial goals.

About Citi:

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management. Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

North America:
Gabriel Morales
+1 718 248 7029
gabriel.morales@citi.com

EMEA:
Allister Fowler
+44 7873 73586
allister.fowler@citi.com

APAC:
Godwin Chellam
+852 2868-7682
godwin.chellam@citi.com

LATAM:
Alex Ravinet
+1 305 420 4292
alexandra.ravinet@citi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye